EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 539 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... September 17, 2025 Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC November 27, 2025 Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells June 14, 2019 Load more HOT NEWS ¿Qué son los biosimilares para el tratamiento del cáncer? EMA Recommends Granting a Marketing Authorisation for Degarelix Accord Doctors Think Woman Has A Brain Tumor, But Then They Open... Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and...
